HC Wainwright Issues Optimistic Estimate for LXRX Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – HC Wainwright increased their Q3 2026 earnings per share estimates for Lexicon Pharmaceuticals in a research report issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.15) EPS and FY2027 earnings at ($0.20) EPS.

LXRX has been the subject of several other research reports. Citigroup upped their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a research report on Monday, May 11th. Zacks Research cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings raised Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Finally, Wall Street Zen lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.55.

Lexicon Pharmaceuticals Trading Down 2.8%

Shares of NASDAQ:LXRX opened at $2.40 on Monday. The company has a market cap of $1.07 billion, a PE ratio of -16.00 and a beta of 1.08. The company’s 50-day moving average price is $2.21 and its 200 day moving average price is $1.87. Lexicon Pharmaceuticals has a fifty-two week low of $1.02 and a fifty-two week high of $2.68. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 37.53% and a negative net margin of 147.38%.The firm had revenue of $0.69 million for the quarter, compared to the consensus estimate of $3.99 million.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP bought a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at $26,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter worth $27,000. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $31,000. Leonteq Securities AG acquired a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at $34,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at $39,000. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.